Dakshina Reddy | Head of Global Regulatory Strategy and Operations
Bill & Melinda Gates Medical Research Institute

Dakshina Reddy, Head of Global Regulatory Strategy and Operations, Bill & Melinda Gates Medical Research Institute

Dakshina Reddy is a regulatory professional with over 25 years’ experience in drug regulatory affairs and clinical research. He has expertise in global drug regulatory strategy, drug development and regulatory life-cycle management. He is experienced in working with leading Regulatory Authorities including US FDA, EMA, PMDA, Health Canada, as well as emerging regulatory bodies in developing markets. Prior to joining Gates MRI, Dakshina held various positions of increasing responsibility, where he contributed towards growing and developing regulatory strategy and establishing teams, leading regulatory programs for expedited review and market approval as well as shaping regulatory markets that enabled increased access. He led and achieved multiple approvals in the US, EU, Japan, Canada, Brazil and Mexico. In his career he worked across a wide range of regulatory therapeutic fields that included Cardiovascular, Metabolism, Respiratory, Neuroscience, Oncology, Immunology and HIV. He previously held positions at Altimmune Inc., Galectin Therapeutics, Novartis Corporation, Amgen, AstraZeneca, and Merck KGaA.  Dakshina holds a degree in Pharmacy from Rhodes University, South Africa and a Master of Science degree in Medicine from the University of the Witwatersrand, South Africa and he continues to be a member of several professional regulatory organizations. 

Appearances:



Main Congress Day 2 - 23rd April @ 12:10

Panel: Strengthening the market and regulatory access of vaccines in Africa

  • How do we increase local vaccine manufacturing capacity and bolster regulatory systems within African nations?
  • The power of fostering regional collaboration on procurement and market dynamics
  • Building capacity for R&D and implementing and strengthening African vaccine manufacturers
  • The need for targeted initiatives to address vaccine hesitancy
last published: 22/Apr/25 22:05 GMT

back to speakers